Fluidic Analytics reels in $31M for development of its protein-characterizing tools

Illustration of three DNA helices
U.K.-based startup Fluidic Analytics reeled in $31 million in a round of fundraising to support the development of its protein-characterizing tools. (Darwin Laganzon)

U.K.-based startup Fluidic Analytics reeled in $31 million in a round of fundraising to support the development of its protein-characterizing tools designed to better understand the biology of conditions like Alzheimer’s disease as well as the interaction between drugs and their targets.

The funding round was led by Draper Esprit. Delin Ventures, BGF, IQ Capital and Amadeus Capital Partners also participated in the round.

Fluidic’s products are based on a proprietary platform developed at the University of Cambridge that allows researchers to delve deeper into how proteins fold, aggregate and interact “by characterizing them in solution—precisely as they exist in the body,” the company said in a release.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market,” Andrew Lynn, Fluidic’s chief executive, said in a statement. “It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world.”

The way proteins behave is important to understanding how diseases develop, identifying the way drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the most optimum time, the company said.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

PPD, which is going public (again) after years of being private, is ramping up its clinical research units (CRUs).

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.